市场调查报告书
商品编码
1267456
自动注射器市场——按类型、给药途径、疗法、最终用途、全球预测,2023-2032 年Autoinjectors Market - By Type, By Route of Administration, By Therapy,, By End-use & Global Forecast, 2023 - 2032 |
全球自动注射器市场预计到 2032 年将呈指数增长,这是由于慢性病的增加导致对靶向治疗的需求不断增长。
此外,新型靶向药物的推出和药物开发投资有望推动自动注射器市场的增长。
此外,对自行服用药物的日益偏爱将推动未来几年的市场需求。 此外,减少大型生物製剂产品组合中使用的设计变更的时间、风险和成本的需求日益增长,预计将推动产品在全球范围内的采用。
全球自动注射器行业的主要参与者继续采取战略举措,例如併购、合作伙伴关係以及引入带有一次性盒和电子驱动器的可重复使用自动注射器。 这些可重复使用的自动注射器包含预填充注射器,在最大限度地使用新药的同时提供针头安全性。 这种新兴市场的发展正在推动更多患者使用自动注射器进行自我治疗,进一步促进市场扩张。
总体而言,全球自动注射器市场在类型、给药途径、治疗、最终用途和区域方面存在分歧。
按类型划分,预计到 2022 年一次性用品的收入份额将超过 370 亿美元,并在 2032 年之前实现显着增长。 这种增长可归因于一次性自动注射器提供的卓越功能,例如以患者为中心和支持完整药物输注的易用性。
按给药途径,肌肉注射器预计会显着增长,因为它们用于过敏反应和过敏反应。 此外,由于它在紧急情况下发挥重要作用,因此有望扩大该领域。
基于治疗,糖尿病细分市场预计将在 2022 年占据超过 23% 的市场份额,并在 2032 年之前呈指数增长。 这种增长是由于糖尿病患者人数的增加和相关费用的增加。 世界卫生组织估计约有 4.22 亿人患有糖尿病。
在最终用途方面,由于自动注射器提供的好处(例如管理过敏反应、糖尿病、急性发作、焦虑等),预计从 2023 年到 2032 年家庭护理环境部分将显着增长。 此外,该产品的易用性、剂量控制和自我管理等特点有望在未来支持细分市场扩张。
按地区划分,预计欧洲自动注射器市场在 2023 年至 2032 年期间的市场份额将超过 20%。 医疗器械行业的兴起、监管框架的变化以及临床试验/证据的透明度是估计刺激欧洲自动注射器行业增长的主要因素。
Global Autoinjectors Market is slated to grow exponentially by 2032, owing to the rising demand for targeted therapies, in light of the growing prevalence of chronic diseases. In addition, introduction to novel targeted medicines and investments in drug development is slated to drive the growth of the autoinjectors market.
Besides, the rising preference for self-administration medication would propel the market demand in the ensuing years. Moreover, the increasing requirement to reduce the time and risk and expense of modifying designs that could be used across large biologic pharmaceutical portfolios are anticipated to foster the product adoption worldwide.
The key players in the global autoinjector industry are continuously incorporating strategic initiatives such as mergers and acquisitions, partnerships, and introducing reusable autoinjectors with disposable cassettes and electronic drive units. These reusable autoinjectors contain prefilled syringes and provide needle safety while maximizing the use of novel drugs. Such developments encourage more patients to use autoinjectors for self-administered medications, further augmenting market expansion.
Overall, the global autoinjectors market is bifurcated in terms of type, route of administration, therapy, end-use, and region.
Considering the type, the disposables segment held over USD 37 billion revenue share in 2022 and is slated to demonstrate massive growth through 2032. The growth can be attributed to the exceptional features offered by disposable autoinjectors, such as being patient-centric and easy operability to support the complete injection of medication.
By route of administration, the intramuscular autoinjectors segment is slated to grow considerably owing to its use for anaphylaxis and allergic reactions. In addition, these autoinjectors play a key role during an emergency, which will further support the segmental expansion.
Based on therapy, the diabetes segment held more than 23% market share in 2022 and is expected to grow exponentially through 2032. The growth can be credited to the rising cases and subsequent increase in expenses of diabetes. As per WHO estimates, approximately 422 million people suffer from diabetes.
By end-use, the homecare settings segment is depicted to grow notably during 2023-2032, owing to the benefits offered by autoinjectors, including managing anaphylaxis, diabetes, acute seizures, anxiety, and others. In addition, the product's capabilities, such as being easy usage, controlled dosage, and self-administrability, are further expected to support the segmental expansion in the future.
Regionally, the Europe global autoinjectors market is slated to exhibit over 20% market share between 2023-2032. The rising medical device industry, changes in the regulatory framework and transparency in the clinical trials/evidence are some key factors that are estimated to stimulate the Europe autoinjector industry growth.